These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19758686)

  • 1. Cryoimmunotherapy in urologic oncology.
    Sidana A; Chowdhury WH; Fuchs EJ; Rodriguez R
    Urology; 2010 May; 75(5):1009-14. PubMed ID: 19758686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy using tumor cryoablation.
    Sidana A
    Immunotherapy; 2014; 6(1):85-93. PubMed ID: 24341887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy approaches in urologic oncology.
    Vieweg J; Gilboa E
    Surg Oncol Clin N Am; 1995 Apr; 4(2):203-18. PubMed ID: 7796281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer.
    Niu L; Chen J; He L; Liao M; Yuan Y; Zeng J; Li J; Zuo J; Xu K
    Pancreas; 2013 Oct; 42(7):1143-9. PubMed ID: 23899940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic overview of current immunotherapy approaches in urologic malignancy.
    Drake CG
    Urol Oncol; 2006; 24(5):413-8. PubMed ID: 16962493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound-based combination therapy: potential in urologic cancer.
    Finley DS; Pouliot F; Shuch B; Chin A; Pantuck A; Dekernion JB; Belldegrun AS
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):107-13. PubMed ID: 21166515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Understanding the concepts in urologic oncology].
    Rübben H
    Urologe A; 1987 Jan; 26(1):1. PubMed ID: 3576858
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biochemical modulation of chemotherapy of urologic malignancies].
    Okada K
    Hinyokika Kiyo; 1993 Dec; 39(12):1195-6. PubMed ID: 8285170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interdisciplinary urologic oncology].
    Meran JG; Schramek P
    Wien Med Wochenschr; 2008; 158(11-12):299. PubMed ID: 18641928
    [No Abstract]   [Full Text] [Related]  

  • 11. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon therapy in urology].
    Kriegmair M; Hofstetter A
    Urologe A; 1989 Mar; 28(2):116-21. PubMed ID: 2470188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open clinical uro-oncology trials in Canada.
    Mackenzie MJ; Rodrigues G; Winquist E
    Can J Urol; 2009 Dec; 16(6):4964-70. PubMed ID: 20003683
    [No Abstract]   [Full Text] [Related]  

  • 18. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.